Atrial fibrillation in hypertrophic cardiomyopathy - A contemporary mini-review

Stylianos Dragasis; Konstantinos Vlachos; Ourania Kariki; Stavroula Koskina; Andromahi Zygouri; Ilias G Patsiotis; Aris Anastasakis; George Athanasopoulos; Konstantinos Ritsatos; Konstantinos Letsas; Michael Efremidis

doi:10.1016/j.hjc.2022.05.002

Atrial fibrillation in hypertrophic cardiomyopathy - A contemporary mini-review

Hellenic J Cardiol. 2022 Sep-Oct:67:66-72. doi: 10.1016/j.hjc.2022.05.002. Epub 2022 May 15.

Affiliations

¹ Onassis Cardiac Surgery Canter, Leof. Andrea Siggrou 356, Kallithea 176 74, Athens, Greece. Electronic address: [email protected].
² Onassis Cardiac Surgery Canter, Leof. Andrea Siggrou 356, Kallithea 176 74, Athens, Greece.
³ General State Hospital of Nikaia "Saint Panteleimon", Greece.

PMID: 35584711
DOI: 10.1016/j.hjc.2022.05.002

Abstract

Hypertrophic cardiomyopathy (HCM) represents the most common genetically inherited cardiovascular disorder and a leading cause of heart failure and sudden cardiac death. Atrial fibrillation (AF) is the most common arrhythmia encountered in HCM patients, primarily due to the process of left atrium dilatation and remodeling. Its presence typically leads to progressive functional decline, increased frequency of heart failure hospitalizations, and increased thromboembolic risk. In this mini-review, we summarize the contemporary data on AF pathophysiology, risk factors, and management in HCM patients suffering from AF.

Keywords: Arterial thromboembolism; Atrial fibrillation; Hypertrophic cardiomyopathy.

Publication types

Review

MeSH terms

Atrial Fibrillation* / complications
Atrial Fibrillation* / epidemiology
Cardiomyopathy, Hypertrophic* / complications
Cardiomyopathy, Hypertrophic* / epidemiology
Death, Sudden, Cardiac / epidemiology
Death, Sudden, Cardiac / etiology
Death, Sudden, Cardiac / prevention & control
Heart Failure* / complications
Humans
Risk Factors
Thromboembolism* / complications
Thromboembolism* / etiology